Work

Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.4_suppl.269

Authors: Katherine Y. Fan, Aaron Tyler Wild, Daniel A. Laheru, Timothy M. Pawlik, Lei Zheng, Dung Thi Le, Phuoc T. Tran, Avani Satish Dholakia, Rachit Kumar, Susannah G. Ellsworth, Amy Hacker-Prietz, Zeshaan Rasheed, Ana De Jesus-Acosta, Matthew Weiss, Martin Makary, John L. Cameron, Ralph H. Hruban, Elliott K. Fishman, Christopher Lee Wolfgang, Joseph M. Herman

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2590762676

Cites:

Cited by: 1

Related to: 10